Mary Cunningham is a reporter for CBS MoneyWatch. Before joining the business and finance vertical, she worked at "60 Minutes," CBSNews.com and CBS News 24/7 as part of the CBS News Associate Program.

(Bloomberg) — Oracle Corp. (ORCL) would recreate and provide security for a new US version of TikTok’s algorithm under a deal taking shape to sell the popular Chinese-owned app to a consortium of ...

The ongoing TikTok-US saga seems close to reaching a conclusion, but we’re not there yet. As details get worked out for a potential Oracle-driven deal, a new Bloomberg report details the plans for ...

TikTok engages more than 170 million Americans with its endless scroll and viral content, but as a potential sale for the popular platform nears, experts are concerned about the future of the app's ...

A senior official in President Donald Trump’s administration says Oracle will receive a copy of TikTok's algorithm to operate for U.S. users WASHINGTON -- Tech giant Oracle will receive a copy of the ...

Hiverge, a startup founded by former Google DeepMind scientists, has raised $5 million. The Cambridge, UK, startup has developed an AI technology to optimize algorithms. BI got an exclusive look at ...

A potential TikTok deal emerged Monday between the US and China, two days before the Trump administration's latest sell or be banned deadline. Now, attention is shifting to the app's Chinese algorithm ...

The White House has answered what had been one of the major outstanding questions regarding its pending deal to transfer TikTok’s US operations to a majority American ownership group: Under the ...

TikTok will not shut down on Wednesday, as President Donald Trump inches nearer to closing a deal with China that will most likely see the app's majority ownership shift to US owners and US-based ...

WASHINGTON (AP) — Tech giant Oracle will spearhead U.S. oversight of the algorithm and security underlying TikTok's popular video platform under the terms of a deal laid out this week by President ...

Pancreatic cancer remains one of the biggest challenges in the field of oncology. Numbers of cases are increasing, and the latest personalized therapies and immunotherapy are not yet yielding results.